Target Name: GBA3
NCBI ID: G57733
Review Report on GBA3 Target / Biomarker Content of Review Report on GBA3 Target / Biomarker
GBA3
Other Name(s): Klotho-related protein | cytosolic glycosylceramidase | klotho-related protein | CBG | cytosolic galactosylceramidase | glucosidase, beta, acid 3 (cytosolic) | Cytosolic glycosylceramidase | Cytosolic glucosylceramidase | glucosidase beta acid 3 | MGC104276 | GLUC | glucosylceramidase beta 3 (gene/pseudogene) | CBGL1 | Glucosylceramidase beta 3 (gene/pseudogene) | MGC126878 | Cytosolic beta-glucosidase-like protein 1 | Glucosidase, beta, acid 3 (cytosolic) | Cytosolic galactosylceramidase | KLRP | Glucosylceramidase beta 3 | Glucosidase beta acid 3 | Cytosolic GCase | Cytosolic beta-glucosidase | cytosolic glucosylceramidase | cytosolic GCase | cytosolic beta-glucosidase-like protein 1 | GBA3_HUMAN | KLrP

GBA3: A Potential Drug Target and Biomarker for Klotho-Related Protein

Klotho-related protein (KLP) is a protein that is expressed in various tissues of the body, including the brain. It is a key component of the neural cell membrane and plays a crucial role in maintaining the structural integrity of the cell. KLP has also been implicated in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

GBA3, a gene that encodes for the protein KLP, has been identified as a potential drug target and biomarker for these disorders. In this article, we will discuss the biology of Klotho-related protein, the discovery of GBA3 as a potential drug target, and its potential as a biomarker for various neurological disorders.

The Biology of Klotho-Related Protein

Klotho-related protein (KLP) is a transmembrane protein that is expressed in various tissues of the body, including the brain. It is a key component of the neural cell membrane and plays a crucial role in maintaining the structural integrity of the cell. KLP has a molecular weight of approximately 120 kDa and consists of two major domains: an N-terminus domain and a C-terminus domain.

The N-terminus domain of KLP contains a unique structural feature known as a heparan sulfate proteoglycan (HSP) domain. This domain is known for its ability to interact with various molecules, including heparan sulfate salts, which are derived from the N-terminus of the protein. The HSP domain is also involved in the regulation of cellular signaling pathways.

The C-terminus domain of KLP contains a unique region known as the K- domain. This region is involved in the interaction between KLP and various signaling molecules, including the protein p180GTP. The K- domain is also involved in the regulation of cellular signaling pathways and is involved in the regulation of cell adhesion, migration, and invasion.

Discovery of GBA3 as a Potential Drug Target

GBA3, a gene that encodes for the protein KLP, has been identified as a potential drug target for various neurological disorders. GBA3 was first identified in a screening experiment using a library of cDNA libraries to identify genes that were expressed in the brain and were enriched for by differential gene expression.

GBA3 has been shown to be involved in various signaling pathways, including the regulation of cell adhesion, migration, and invasion. It has also been shown to play a role in the regulation of cellular signaling pathways, including the regulation of cell proliferation and the regulation of cell death.

Furthermore, GBA3 has been shown to be involved in the development and progression of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. It has been shown to be involved in the regulation of the expression of genes involved in these disorders, including the regulation of the expression of genes involved in neurotransmitter synthesis and the regulation of the expression of genes involved in neuroprotective enzymes.

GBA3 has also been shown to be involved in the regulation of cellular signaling pathways that are involved in pain perception and neuropathic pain. It has been shown to play a role in the regulation of the expression of genes involved in pain perception and neuropathic pain, including the regulation of the expression of genes involved in neurotransmitter synthesis and the regulation of the expression of genes involved in neuroprotective enzymes.

Potential as a Biomarker

GBA3 has also been shown to be potential as a biomarker for various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. GBA3 has been shown to be involved in the regulation of the expression of genes involved in

Protein Name: Glucosylceramidase Beta 3 (gene/pseudogene)

Functions: Neutral cytosolic beta-glycosidase with a broad substrate specificity that could play a role in the catabolism of glycosylceramides (PubMed:11389701, PubMed:11784319, PubMed:20728381, PubMed:26724485, PubMed:17595169, PubMed:33361282). Has a significant glucosylceramidase activity in vitro (PubMed:26724485, PubMed:17595169). However, that activity is relatively low and its significance in vivo is not clear (PubMed:26724485, PubMed:17595169, PubMed:20728381). Hydrolyzes galactosylceramides/GalCers, glucosylsphingosines/GlcSphs and galactosylsphingosines/GalSphs (PubMed:17595169). However, the in vivo relevance of these activities is unclear (PubMed:17595169). It can also hydrolyze a broad variety of dietary glycosides including phytoestrogens, flavonols, flavones, flavanones and cyanogens in vitro and could therefore play a role in the metabolism of xenobiotics (PubMed:11784319). Possesses transxylosylase activity in vitro using xylosylated ceramides/XylCers (such as beta-D-xylosyl-(1<->1')-N-acylsphing-4-enine) as xylosyl donors and cholesterol as acceptor (PubMed:33361282). Could also play a role in the catabolism of cytosolic sialyl free N-glycans (PubMed:26193330)

The "GBA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GBA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

GBAP1 | GBE1 | GBF1 | GBGT1 | GBP1 | GBP1P1 | GBP2 | GBP3 | GBP4 | GBP5 | GBP6 | GBP7 | GBX1 | GBX2 | GC | GCA | GCAT | GCC1 | GCC2 | GCC2-AS1 | GCDH | GCFC2 | GCG | GCGR | GCH1 | GCHFR | GCK | GCKR | GCLC | GCLM | GCM1 | GCM2 | GCN1 | GCNA | GCNT1 | GCNT1P3 | GCNT2 | GCNT3 | GCNT4 | GCNT7 | GCOM1 | GCSAM | GCSAML | GCSAML-AS1 | GCSH | GCSHP3 | GCSIR | GDA | GDAP1 | GDAP1L1 | GDAP2 | GDE1 | GDF1 | GDF10 | GDF11 | GDF15 | GDF2 | GDF3 | GDF5 | GDF6 | GDF7 | GDF9 | GDI1 | GDI2 | GDI2P1 | GDNF | GDNF Family Receptor alpha | GDNF-AS1 | GDPD1 | GDPD2 | GDPD3 | GDPD4 | GDPD5 | GDPGP1 | GEM | GEMIN2 | GEMIN4 | GEMIN5 | GEMIN6 | GEMIN7 | GEMIN8 | GEMIN8P1 | GEMIN8P4 | GEN1 | general transcription factor IIF (TFIIF) | General transcription factor IIH | Geranylgeranyl transferase | Geranylgeranyl transferase type-1 | GET1 | GET3 | GET4 | GFAP | GFER | GFI1 | GFI1B | GFM1 | GFM2 | GFOD1 | GFOD2 | GFPT1